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The inherent tradeoff between sensitivity and specificity in the 
detection of unexplained antibodies has been the objective of 
many studies, editorials, and journal articles. Many publications 
note that no method is capable of detecting all clinically 
significant antibodies while avoiding all clinically insignificant 
antibodies. This study describes the frequency of nonspecific 
reactivity and unexplained reactivity in solid-phase testing, along 
with the subsequent development of specific antibodies (Abs). 
In this study, nonspecific reactivity (NS) is defined as method-
specific panreactivity detected by solid-phase testing only, with 
no reactivity in other methods. Unexplained reactivity (UR) is 
defined as reactivity present and detectable in all test methods 
after all clinically significant antibodies were ruled out following 
a standard antibody identification algorithm using selected cell 
panels. This retrospective study evaluated antibody detection 
tests of patients at a single center for 2 years using two automated 
solid-phase instruments that used the same three-cell antibody 
detection test. Antibody identification was performed with solid-
phase panels supplemented with a polyethylene glycol tube 
method as needed. Of the 1934 (5%) samples with a positive 
antibody detection test, 29 had unavailable work-up data, 
leaving 1905 (98.5%) samples eligible for inclusion in the study. 
The data revealed the following: Ab only 999 (52.4%); UR only 
429 (22.5%); Ab and UR 227 (11.9%); NS only 206 (10.8%); Ab 
and NS 24 (1.3%); UR and NS 14 (0.7%); and Ab, UR, and NS 
6 (0.3%). Patients with a positive follow-up antibody detection 
test had UR and NS replaced with a specific Ab in 23 of 656 UR 
(3%) and 8 of 230 NS (3%) cases, respectively. Additionally, six 
patients with UR developed a specific Ab along with persistent 
UR, and no patients with persistent NS developed a specific Ab. 
The study concluded that both UR and NS can be encountered in 
solid-phase testing, and both UR and NS can persist in follow-up 
testing. Specific Ab was observed to replace UR in a few patients. 
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Transfusion medicine professionals have the responsibility 
to identify and provide compatible blood components for 
transfusion to their patients. This responsibility includes 
the detection and identification of unexplained antibodies. 
According to the 18th edition of the AABB Technical Manual, 
the goals of antibody detection are to detect in a timely manner 
as many clinically significant antibodies as possible while 
avoiding as many clinically insignificant antibodies.1
This inherent tradeoff between sensitivity and specificity 
in the detection of unexplained antibodies has been the 
objective of many studies, editorials, and journal articles. 
Although all these publications note that no method is 
capable of detecting all clinically significant antibodies 
while avoiding all clinically insignificant antibodies, some of 
these studies reported decreased detection of insignificant 
antibodies by gel,2 and others noted the superior detection 
of clinically significant antibodies by solid-phase testing.3 In 
their study, Liu and Grossman4 noted that in gel an “antibody 
of undetermined specificity (AUS) was reported 1442 times 
(18%) and was the single most reported event” of the 8121 
antibodies evaluated. In the same study, they document that 
in patients presenting with AUS for the first time, the majority 
of AUS persist in subsequent workups and that some AUSs 
even develop into clinically significant antibodies.4 The 2017 
study by Miller et al.5 noted the increased sensitivity of general 
nonspecific reactivity in solid-phase testing when compared 
with tube method testing using polyethylene glycol (PEG) 
and recommends this nonspecific reactivity to not be ignored 
because of the noteworthy proportion of these antibodies that 
develop into specific and clinically significant antibodies. The 
Miller et al. study, however, did not focus on the frequency with 
which nonspecific reactivity might progress to the level of true 
antigen specificity, as did the Liu and Grossman study of the 
gel method. In our current study, nonspecific reactivity (NS) 
is defined as method-specific panreactivity detected by solid-
phase testing only, with no reactivity in other methods. This 
reactivity is in contrast to unexplained reactivity (UR), defined 
as reactivity present and detectable in all test methods after 
all clinically significant antibodies were ruled out following 
our standard antibody identification algorithm using selected 
cell panels.6 Our data analysis attempts to enumerate the 
frequency of UR and NS as well as evaluate their association 
with development of specific antibodies (Abs) over time.
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Materials and Methods
This retrospective study evaluated the antibody detection 
test results of patients between 1 January 2012 and 31 
December 2013. In this single facility, for the time period under 
evaluation, all antibody detection tests were performed on two 
different automated instruments (Echo and Galileo; Immucor, 
Norcross, GA). Both instruments use the same three-cell 
antibody detection test plates (Capture-R Ready-Screen, 
Immucor) to reduce ambiguity between donor cells. Antibody 
detection test results were read and graded by the automated 
instruments or by a medical laboratory scientist who read and 
graded (negative, weak+, 1+, 2+, 3+, or 4+) results according to 
method 1–9 in the AABB Technical Manual.1
In the instance of a positive antibody detection test result, 
the patient’s historical antibody records were reviewed in 
addition to the ensuing antibody identification performed on 
the current sample. Antibody identification was performed 
primarily with solid-phase panels (Capture-R Ready-ID, 
Capture-R Ready-ID Extend I and Extend II; Immcor). If 
needed, this testing was supplemented with a PEG additive 
(Gamma PeG, Immucor) tube method using a 10-minute 
incubation. Antibody reactions were read and graded by the 
same methods as previously described.
An observation of UR or NS resulted in reviewing the past 
records of the associated patient and evaluating subsequent 
samples for the presence of UR and/or NS and for the 
development of specific Abs. Based on the results of the follow-
up testing of these subsequent samples, patients were assigned 
to one of the following categories:
• Category 1: No testing performed
• Category 2: Positive antibody detection test; antibody 
identification unresolved
• Category 3: Negative antibody detection test
• Category 4: Positive antibody detection test; UR or NS 
replaced by specific Ab
• Category 5: Positive antibody detection test; UR or NS 
only remained
Results
In the 24-month study period, antibody detection testing 
was performed on a total of 38,178 patients. Of these, 1934 
(5%) had a positive antibody detection test. The antibody 
identification workup was unavailable for 29 of these patients, 
leaving 1905 (98.5%) eligible for inclusion in this study.
Results of antibody identification testing revealed UR was 
present in 917 of 1905 (48%) patients, and NS was present in 
250 of 1905 (13%) patients. The various combinations of Ab, 
UR, and NS were as follows: Ab only 999 (52.4%); UR only 
429 (22.5%); Ab and UR 227 (11.9%); NS only 206 (10.8%); 
Ab and NS 24 (1.3%); UR and NS 14 (0.7%); and Ab, UR, and 
NS 6 (0.3%). For the samples in which UR and NS were both 
noted, UR was detected in a different antibody identification 
method (PEG tube) after NS was detected in the solid-phase 
method. The results are summarized in Table 1. There was a 
history of a specific Ab in 141 of 656 (21%) patients with UR 
and in 42 of 230 (18%) patients with NS.
For samples in which UR or NS was observed, follow-up 
testing of subsequent samples was evaluated, and the patients 
were assigned to one of the following categories:
• Category 1: No testing performed in 326 of 656 UR 
(50%) and 129 of 230 NS (56%)
• Category 2: Positive antibody detection test; antibody 
identification unresolved in 89 of 656 UR (14%) and 51 
of 230 NS (22%)
• Category 3: Negative antibody detection test in 178 of 
656 UR (27%) and 23 of 230 NS (10%)
• Category 4: Positive antibody detection test; UR or NS 
replaced by specific Ab in 23 of 656 UR (3%) and 8 of 
230 NS (3%)
• Category 5: Positive antibody detection test; UR only 
remained in 40 of 656 UR (new specific antibody 
developed in 6 of 40 of these) or NS only in 19 of 230 NS
Category 4 and 5 results are graphically depicted in 
Figure 1.
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Table 1. Solid-phase antibody evaluation summary
Antibody work-up results (N = 1905)
n %*
Antibody only 999 52.4
Unexplained reactivity only 429 22.5
Antibody and unexplained reactivity 227 11.9
Nonspecific reactivity only 206 10.8
Antibody and nonspecific reactivity 24 1.3
Unexplained reactivity and nonspecific 
reactivity 14 0.7
Antibody, unexplained reactivity, and 
nonspecific reactivity 6 0.3
*Percent of total, rounded to nearest 0.1%.
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Discussion
Our data also shed light on the constant balance between 
sensitivity and specificity. During follow-up testing, we 
determined the development from UR and/or NS to true Ab 
specificity. Those samples in categories 1 and 2 can be omitted 
because of either a lack of follow-up or no resolution of specific 
antibody identification. Of those samples with evaluable follow-
up antibody detection and identification in categories 3, 4, and 
5, UR was undetectable in 201 of 241 (83%) and persisted in 
40 of 241 (17%), and NS was undetectable in 31 of 50 (62%) 
and persisted in 19 of 50 (38%). Specific Ab development in 
patients in categories 3, 4, and 5 occurred in 29 of 241 (12%) 
of previous UR and 8 of 50 (16%) of NS. Figure 1 depicts the 
specific Abs identified in place of the UR/NS.
Of interest is that during the study period, the 
manufacturer (Immucor) alerted users to an increase in UR 
reported to them by their customers. Steps were taken during 
reagent manufacturing, and resolution of the increase in UR 
was communicated to users based on customer reports. To 
Fig. 1 (A) Unexplained reactivity (UR) replaced with antibodies and reactivity, as shown. (B) Nonspecific reactivity (NS) replaced with 
antibodies and reactivity, as shown. HLA = human leukocyte antigen.
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determine whether the UR alert affected UR and NS rates 
at our facility, the study periods before, during, and after the 
alert period were compared. Based on the issuance date of the 
alert (22 March 2013), the pre-alert period was defined as 1 
January 2012 through 30 September 2012, the alert period 
was defined as 1 October 2012 through 30 April 30 2013, and 
the post-alert period was defined as 1 May 2013 through 31 
December 2013.
A decrease in the rate of UR and NS after the alert period 
was noted on the smaller instrument (Echo, Immucor) (Fig. 2). 
There was a 26 percent overlap of patients with antibody 
detection performed on either instrument (Galileo or Echo, 
Immucor) on different dates, but because of the retrospective 
nature of the study and the relatively small numbers, no 
further trend was apparent in distinguishing UR and NS on 
the two solid-phase devices. Further studies are in progress at 
this facility to fully evaluate the impact of the improvements 
communicated on the UR and NS rates. Additionally, these 
subsequent studies use a newer instrument (Galileo NEO, 
Immucor) and will generate data as a second phase to this 
original study with the updated automated instrument.
Conclusions
The patients who have evaluable follow-up antibody 
detection testing are described in categories 3, 4, and 5. Based 
on analysis of the testing performed on samples from these 
patients, it can be concluded that UR and NS antibodies are 
encountered in solid-phase testing and may be transient. In 
these patients, the UR was undetectable in 201 of 241 (83%) 
and persisted in 40 of 241 (17%) of the patients on follow-up 
testing. Also, the NS was undetectable in 31 of 50 (62%) and 
persisted in 19 of 50 (38%) of the patients upon follow-up 
testing.
UR and NS antibodies detected in solid-phase testing may 
develop into true antibody specificity. Of those patients with 
evaluable follow-up antibody detection tests (categories 3, 4, 
and 5), a new antibody developed in 29 of 241 patients with 
a previous UR (12%) and in 8 of 50 patients with a previous 
NS (16%). Based on a high regard for patient safety, which 
includes the maximum detection of clinically significant 
antibodies, this facility has selected the automated solid-phase 
method—knowing the rate of UR and NS—because of the well-
documented superior sensitivity of Capture-R3,7 compared 
with other testing methods such as tube testing.
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Fig. 2 The frequency of unexplained reactivity (UR)/nonspecific reactivity (NS) changed during the study period, which overlapped with 
the manufacturer’s alert regarding UR/NS. The pre-alert period is defined as 1 January 2012 to 30 September 2012, the alert period is 1 
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